Literature DB >> 23867809

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.

Amit S Patel1, Richard J Siegert, Gregory J Keir, Sabrina Bajwah, Richard D Barker, Toby M Maher, Elisabetta A Renzoni, Athol U Wells, Irene J Higginson, Surinder S Birring.   

Abstract

Health status and forced vital capacity (FVC) are widely used outcome measures of interstitial lung disease (ILD) but there is a paucity of studies reporting the minimal clinically meaningful change in these parameters. A study was undertaken to assess the minimal important difference (MID) of an ILD specific health status questionnaire, the King's Brief ILD questionnaire (K-BILD) and that of FVC in a range of ILDs. 57 patients with ILD (17 idiopathic pulmonary fibrosis; IPF) completed the K-BILD (score range 0-100) at 2 separate clinic visits. Patients underwent spirometry at both visits. The MID was determined by a range of distribution methods (Standard error of mean: SEM and 0.3× Effect size: ES) and anchor based methods (objective: FVC and subjective: global rating of change questionnaires, GRCQ). The MID was derived by calculating an average of all methods. Health status was reduced at baseline in all patients, mean (SD) K-BILD total score 62(23). The average MID for K-BILD total score incorporating all methods was an 8 unit change (range 6-10). The average MID for FVC was a 6% change of baseline (range 4-7%). The K-BILD is a responsive patient reported outcome measure for patients with ILD. It can potentially be used to assess patients in the clinic and evaluate the response to therapy. The MID of the K-BILD total score is 8 units. The MID for FVC for a range of ILDs was 6%, similar to that reported recently for patients with IPF. Our findings will facilitate the clinical interpretation of health status and FVC data in ILD.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Interstitial lung disease; Minimal clinically important difference; Quality of life

Mesh:

Year:  2013        PMID: 23867809     DOI: 10.1016/j.rmed.2013.06.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  14 in total

Review 1.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

2.  Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Authors:  Monique Wapenaar; Amit S Patel; Surinder S Birring; Ron T van Domburg; Eric Wp Bakker; Virginia Vindigni; C Magnus Sköld; Vincent Cottin; Carlo Vancheri; Marlies S Wijsenbeek
Journal:  Chron Respir Dis       Date:  2016-12-26       Impact factor: 2.444

3.  Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.

Authors:  Robert P Baughman; Rohit Gupta; Marc A Judson; Elyse E Lower; Surinder S Birring; Jeffrey Stewart; Rebecca Reeves; Athol U Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

Review 4.  Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Authors:  Amy L Olson; Kevin K Brown; Jeffrey J Swigris
Journal:  Patient Relat Outcome Meas       Date:  2016-05-17

5.  Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Authors:  Dina Visca; Vicky Tsipouri; Letizia Mori; Ashi Firouzi; Sharon Fleming; Morag Farquhar; Elizabeth Leung; Toby M Maher; Paul Cullinan; Nick Hopkinson; Athol U Wells; Winston Banya; Jennifer A Whitty; Huzaifa Adamali; Lisa G Spencer; Piersante Sestini; Elisabetta A Renzoni
Journal:  Trials       Date:  2017-04-28       Impact factor: 2.279

6.  Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.

Authors:  Boglárka Lilla Szentes; Michael Kreuter; Thomas Bahmer; Surinder S Birring; Martin Claussen; Julia Waelscher; Reiner Leidl; Larissa Schwarzkopf
Journal:  Respir Res       Date:  2018-05-25

7.  Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial.

Authors:  Andrew W Creamer; Shaney L Barratt
Journal:  Breathe (Sheff)       Date:  2019-06

8.  The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Authors:  Aish Sinha; Amit Suresh Patel; Richard J Siegert; Sabrina Bajwah; Toby M Maher; Elizabeth A Renzoni; Athol U Wells; Irene J Higginson; Surinder S Birring
Journal:  BMJ Open Respir Res       Date:  2019-02-18

9.  Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Authors:  Kevin R Flaherty; Kevin K Brown; Athol U Wells; Emmanuelle Clerisme-Beaty; Harold R Collard; Vincent Cottin; Anand Devaraj; Yoshikazu Inoue; Florence Le Maulf; Luca Richeldi; Hendrik Schmidt; Simon Walsh; William Mezzanotte; Rozsa Schlenker-Herceg
Journal:  BMJ Open Respir Res       Date:  2017-09-17

Review 10.  Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

Authors:  Bridget A Graney; Joyce S Lee
Journal:  Patient Relat Outcome Meas       Date:  2018-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.